FDA breakthrough status gives Coredio’s AI heart failure platform a faster regulatory path
Coredio’s AI heart failure platform may bring hemodynamic insight into home care. See why FDA breakthrough status matters now.
Can AI help Biomunex find better bispecific antibody targets in cancer?
AI may speed cancer drug discovery, but Biomunex’s bigger test is whether smarter target pairing can translate into stronger immunotherapies.
Drug discovery has an AI problem. Clicklinks thinks the answer is connection, not just algorithms
Find out how Sanyou Bio’s Clicklinks platform could reshape AI-led drug discovery by linking biotech, CRO, CDMO and preclinical resources.
Can Anthropic’s Claude help Bristol Myers Squibb speed up medicine discovery and delivery?
Bristol Myers Squibb is moving AI from pilots to enterprise scale. Claude’s real test is governance, data trust and drug development impact.
Can ArteraAI Breast turn routine pathology slides into breast cancer risk intelligence?
AI can read pathology slides, but can it change breast cancer treatment decisions? ArteraAI Breast puts that question before clinicians and payers.
Are autonomous labs quietly turning biopharma researchers into scientific strategists?
Autonomous labs can run experiments faster. The bigger shift is what happens when biopharma researchers stop executing and start directing.
Merck KGaA just made a quiet digital-health move. Could hybrid drugs be pharma’s next big reset?
Digital therapeutics struggled alone. Remepy and Merck KGaA are testing whether software works better when built into the drug itself.
Why Abbott’s Ultreon 3.0 could reshape stent planning in complex coronary disease
AI can now guide coronary imaging in real time. Abbott’s Ultreon 3.0 puts precision PCI closer to routine clinical workflow.
From ARPA-H to Basilea: What Phare Bio’s new deal reveals about biotech partnerships
Phare Bio and Basilea partner to develop an AI-designed antibiotic for deadly gram-negative infections. Explore what this deal could mean for the future of antimicrobial R&D.
Lilly’s $40m commitment to IU aims to transform Alzheimer’s research and trials
Eli Lilly and Indiana University are launching a $40M clinical trial and Alzheimer’s research initiative in Indiana. See what it could mean for U.S. pharma.